Article: Role of STAT3/5 and Bcl-2/xL in 2-methoxyestradiol-induced endoreduplication of nasopharyngeal carcinoma cells

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleRole of STAT3/5 and Bcl-2/xL in 2-methoxyestradiol-induced endoreduplication of nasopharyngeal carcinoma cells
AuthorsTing, CM2
Wong, CK2
Wong, RNS2
Lo, KW4
Lee, AW3
Tsao, GS1
Lung, ML1
Mak, NK2
Keywords2-Methoxyestradiol
Bcl-2/Xl
Endoreduplication
Nasopharyngeal Carcinoma
Stat3/5
Issue Date2012
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.interscience.wiley.com/jpages/0899-1987/
CitationMolecular Carcinogenesis, 2012, v. 51 n. 12, p. 963-972 [How to Cite?]
DOI: http://dx.doi.org/10.1002/mc.20867
Abstract2-methoxyestradiol (2ME2), an endogenous metabolite of 17-β-estradiol, has been shown to induce apoptosis and cell cycle arrest in various tumor models. We have previously shown that 2ME2 induced endoreduplication in a well-differentiated nasopharyngeal carcinoma (NPC) HK-1 and a poorly differentiated C666-1 cell line. In the present study, we studied the survival factors involved in 2ME2-induced endoreduplicating NPC cells. In the HK-1 cells, knockdown of BcL-xL expression by siRNA resulted in the reduction of endoreduplication and an increase in the percentage of apoptosis. Further mechanistic study revealed that 2ME2 enhanced the expression of the phosphorylated form of STAT5 (p-STAT5-Y694), but not p-STAT3 (Y705) and p-STAT3 (S727), in the nucleus of HK-1 cells. Pre-treatment of cells with JAK/STAT inhibitor AG490 and STAT5 inhibitor resulted not only in the reduced expression of Bcl-xL, but also reduced the percentage of endoreduplicating cells. In contrast, 2ME2 enhanced the expression of p-STAT3 in the poorly differentiated C666-1 cells. Pharmacological inhibition of STAT3 or Bcl-2/xL resulted in a decrease in endoreduplication of C666-1 cells. Taken together, the expression of p-STAT5 and p-STAT3 was upregulated in 2ME2-induced endoreduplicating HK-1 and C666-1 cells, respectively. Combination of 2ME2 with Bcl-2/xL inhibitor is a novel strategy to reduce the formation of endoreduplicating cells during chemotherapeutic treatment of NPC. © 2011 Wiley Periodicals, Inc.
ISSN0899-1987
2011 Impact Factor: 3.164
2011 SCImago Journal Rankings: 0.347
DOIhttp://dx.doi.org/10.1002/mc.20867
DC Field
Value
dc.contributor.authorTing, CM
dc.contributor.authorWong, CK
dc.contributor.authorWong, RNS
dc.contributor.authorLo, KW
dc.contributor.authorLee, AW
dc.contributor.authorTsao, GS
dc.contributor.authorLung, ML
dc.contributor.authorMak, NK
dc.date.accessioned2012-06-26T05:58:19Z
dc.date.available2012-06-26T05:58:19Z
dc.date.issued2012
dc.description.abstract2-methoxyestradiol (2ME2), an endogenous metabolite of 17-β-estradiol, has been shown to induce apoptosis and cell cycle arrest in various tumor models. We have previously shown that 2ME2 induced endoreduplication in a well-differentiated nasopharyngeal carcinoma (NPC) HK-1 and a poorly differentiated C666-1 cell line. In the present study, we studied the survival factors involved in 2ME2-induced endoreduplicating NPC cells. In the HK-1 cells, knockdown of BcL-xL expression by siRNA resulted in the reduction of endoreduplication and an increase in the percentage of apoptosis. Further mechanistic study revealed that 2ME2 enhanced the expression of the phosphorylated form of STAT5 (p-STAT5-Y694), but not p-STAT3 (Y705) and p-STAT3 (S727), in the nucleus of HK-1 cells. Pre-treatment of cells with JAK/STAT inhibitor AG490 and STAT5 inhibitor resulted not only in the reduced expression of Bcl-xL, but also reduced the percentage of endoreduplicating cells. In contrast, 2ME2 enhanced the expression of p-STAT3 in the poorly differentiated C666-1 cells. Pharmacological inhibition of STAT3 or Bcl-2/xL resulted in a decrease in endoreduplication of C666-1 cells. Taken together, the expression of p-STAT5 and p-STAT3 was upregulated in 2ME2-induced endoreduplicating HK-1 and C666-1 cells, respectively. Combination of 2ME2 with Bcl-2/xL inhibitor is a novel strategy to reduce the formation of endoreduplicating cells during chemotherapeutic treatment of NPC. © 2011 Wiley Periodicals, Inc.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationMolecular Carcinogenesis, 2012, v. 51 n. 12, p. 963-972 [How to Cite?]
DOI: http://dx.doi.org/10.1002/mc.20867
dc.identifier.doihttp://dx.doi.org/10.1002/mc.20867
dc.identifier.hkuros202589
dc.identifier.issn0899-1987
2011 Impact Factor: 3.164
2011 SCImago Journal Rankings: 0.347
dc.identifier.scopuseid_2-s2.0-84867743723
dc.identifier.urihttp://hdl.handle.net/10722/149770
dc.languageeng
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.interscience.wiley.com/jpages/0899-1987/
dc.publisher.placeUnited States
dc.relation.ispartofMolecular Carcinogenesis
dc.subject2-Methoxyestradiol
dc.subjectBcl-2/Xl
dc.subjectEndoreduplication
dc.subjectNasopharyngeal Carcinoma
dc.subjectStat3/5
dc.titleRole of STAT3/5 and Bcl-2/xL in 2-methoxyestradiol-induced endoreduplication of nasopharyngeal carcinoma cells
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong
  2. Hong Kong Baptist University
  3. Pamela Youde Nethersole Eastern Hospital
  4. Chinese University of Hong Kong